Recruiting

NCT Number: NCT07480720

Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Graves Disease Autoimmune Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Endocrine System Diseases Exophthalmos Eye Diseases Eye Diseases, Hereditary Genetic Diseases, Inborn Goiter Graves Ophthalmopathy Hyperthyroidism Immune System Diseases Orbital Diseases Thyroid Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fethi Sekin City Hospital

Elâzığ, Elaziğ, Turkey (Türkiye)

Location status: Recruiting

Location contact

SİNEM KESER, MD

CONTACT

[email protected]

+905070646384

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years

Diagnosis of Graves' disease (for the patient group)

No known thyroid disease in healthy control participants

Availability of optical coherence tomography (OCT) measurements and laboratory data

Time interval between OCT examination and blood sampling ≤ 10 days

Exclusion criteria

Presence of glaucoma, optic neuropathy, or retinal vascular diseases

Macular diseases, uveitis, or severe refractive error (high myopia >6 diopters)

Diabetic retinopathy

History of previous intraocular surgery

History of active infection, malignancy, or systemic inflammatory disease

Poor-quality OCT measurements (segmentation errors or low signal strength)

Treatment and study plan

Primary outcomes

Peripapillary Retinal Nerve Fiber Layer Thickness

Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026

Evaluation and comparison of peripapillary retinal nerve fiber layer thickness values in different quadrants among study groups.
Macular Thickness Measured by Optical Coherence Tomography

Time frame: Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026

Comparison of macular thickness measurements among healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy.

Study contacts

Contact information is provided by the study sponsor or research team.

SİNEM KESER, MD

CONTACT

[email protected]

+905070646384

Sponsors and collaborators

Lead sponsor

Elazıg Fethi Sekin Sehir Hastanesi

Other

Registry information

Official study title

Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Mar 18, 2026
Registry last updated: Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting